NASDAQ / LIVE COMPANY INTELLIGENCE

Biodesix, Inc.

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERBDSX
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / BDSX COVERAGE

What’s moving Biodesix, Inc. now

Current reporting with the operating signal separated from the noise.

01
MarketBeat

Stempoint Capital LP Acquires New Holdings in Biodesix, Inc. $BDSX

The story matters when it changes Biodesix, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
Biodesix, Inc.: Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Biodesix, Inc.: Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

The story matters when it changes Biodesix, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript

Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript

Investors are testing whether Biodesix, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
04
Biodesix, Inc. to Release Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Biodesix, Inc. to Release Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

The story matters when it changes Biodesix, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Biodesix, Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2024 with Significant Revenue Growth

Biodesix, Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2024 with Significant Revenue Growth

Investors are testing whether Biodesix, Inc.’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors

Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors

The story matters when it changes Biodesix, Inc.’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest BDSX filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

10-QQuarterly financial reportFiled 2026-05-04 · Period 2026-03-31SEC ↗10-QQuarterly financial reportFiled 2025-11-03 · Period 2025-09-30SEC ↗10-KAnnual financial reportFiled 2026-02-26 · Period 2025-12-31SEC ↗8-KMaterial company eventFiled 2026-05-20 · Period 2026-05-19SEC ↗8-KMaterial company eventFiled 2026-05-04 · Period 2026-05-04SEC ↗8-KMaterial company eventFiled 2026-02-26 · Period 2026-02-26SEC ↗DEF 14AProxy and shareholder meetingFiled 2026-04-09 · Period 2026-05-19SEC ↗4Official SEC filingFiled 2026-07-02 · Period 2026-06-30SEC ↗
EARNINGS / QUARTERLY TRACKER

Biodesix, Inc., quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.

Q4

Fourth quarter / full year

SEARCH Q4 COVERAGE →